Zacks Investment Research downgraded shares of Tyme Technologies (NASDAQ:TYME) from a buy rating to a hold rating in a research report sent to investors on Friday.

According to Zacks, “Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body’s immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. “

TYME has been the subject of a number of other reports. Canaccord Genuity reaffirmed a buy rating on shares of Tyme Technologies in a research report on Friday, June 15th. BidaskClub lowered Tyme Technologies from a sell rating to a strong sell rating in a research report on Friday, August 10th. Finally, HC Wainwright reaffirmed a buy rating and set a $9.50 target price on shares of Tyme Technologies in a research report on Thursday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $7.31.

NASDAQ TYME traded down $0.10 on Friday, reaching $2.53. 187,207 shares of the stock traded hands, compared to its average volume of 295,916. The firm has a market cap of $281.41 million, a PE ratio of -12.05 and a beta of 0.18. Tyme Technologies has a 12 month low of $2.01 and a 12 month high of $8.30.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers bought a new position in shares of Tyme Technologies in the 2nd quarter worth $110,000. Schwab Charles Investment Management Inc. bought a new position in shares of Tyme Technologies in the 2nd quarter worth $248,000. Bank of New York Mellon Corp bought a new position in shares of Tyme Technologies in the 2nd quarter worth $267,000. Perkins Capital Management Inc. raised its position in shares of Tyme Technologies by 330.0% in the 2nd quarter. Perkins Capital Management Inc. now owns 101,050 shares of the company’s stock worth $319,000 after acquiring an additional 77,550 shares in the last quarter. Finally, Northern Trust Corp bought a new position in shares of Tyme Technologies in the 2nd quarter worth $1,181,000. 11.13% of the stock is owned by hedge funds and other institutional investors.

About Tyme Technologies

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Featured Article: Book Value Of Equity Per Share – BVPS Explained

Get a free copy of the Zacks research report on Tyme Technologies (TYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.